OR-RADISYS-CORPORATION
9.3.2022 14:02:06 CET | Business Wire | Press release
Radisys® Corporation , a global leader of open telecom solutions, today announced that Korean small cells player Qucell Networks is leveraging Radisys' Connect RAN gNodeB software to enable and deploy 5G small cell solutions for global markets. The integrated commercial-grade 5G small cell solution is being trialed in multiple operators’ networks across the globe.
Radisys’ 3GPP-compliant Connect RAN 5G software enables an elastic and agile 5G network tailored to meet the unique requirements of diverse 5G applications with minimized CAPEX, improved time-to-market, and shortened time-to-revenue. Qucell Networks’ 5G small cells meet varied requirements and enable multiple deployment scenarios in mmWave, Sub-6 GHz, Non-Standalone (NSA), Standalone (SA) and support advanced use cases in residential, enterprise, and outdoor scenarios.
News Highlights
- Radisys’ Connect RAN gNodeB software enables Qucell Networks’ 5G small cells to support high capacity, robust connectivity, low latency and secure 5G networks for advanced uses cases such as smart factories, healthcare, education, stadiums, enterprises, retail and other private 5G use cases.
- The ruggedized and feature-rich 5G small cell solution from Radisys and Qucell offers operators a commercial-grade, deployment-ready solution.
- Radisys’ Connect RAN 5G is the first-to-market protocol software compliant with 3GPP Release 16 and delivers enhancements in functionality, capacity, coverage, latency, mobility, reliability, and ease of deployment. It also supports the FAPI and nFAPI specifications from the Small Cell Forum (SCF), and it is compliant with O-RAN Alliance architecture. Connect RAN 5G software won the SCF Small Cell Award for Outstanding Contribution to Small Cell Open RAN Platforms.
- The software is available integrated on multiple industry-leading platforms to accelerate global 5G deployments.
“We are seeing growing demand for 5G small cells as global operators roll out their 5G networks and enterprises seek to deploy 5G private networks,” said Munish Chhabra, SVP and General Manager, Software and Services, Radisys. “We’ve teamed with Qucell to meet this demand with a pre-integrated, feature-rich solution for our customers.”
“We are excited to partner with Radisys on 5G small cells that deliver robust connectivity and high performance for a variety of indoor and outdoor use cases,” said Young-Soo Kwak, CEO, Qucell Networks. “Radisys is the leader in 5G software, and this integrated solution offers our joint customers an easy path to 5G deployment.”
About Radisys
Radisys is a global leader in open telecom solutions and services. Its disaggregated platforms and integration services leverage open reference architectures and standards combined with open software and hardware, enabling service providers to drive open digital transformation. Radisys offers an end-to-end solutions portfolio from digital endpoints to disaggregated and open access and core solutions, to immersive digital applications and engagement platforms. Its world-class and experienced network services organization delivers full lifecycle services to help service providers build and operate highly scalable and high-performance networks at optimum total cost of ownership. For more information, visit www.Radisys.com .
About Qucell Networks
Qucell Networks is a 5G and LTE small cells vendor and solutions provider. World-class mobile network operators have been deploying Qucell LTE solutions since 2012. What differentiates Qucell from competitors is a proven and commercially ready comprehensive suite of LTE and 5G small cells solutions. Qucell offers timely, effective turnkey products to solve real problems in commercial environments. Qucell partnerships with pioneers in small cells technology have resulted in proven cutting-edge products and professional services. For more information, visit QUCELL .
Radisys® is a registered trademark of Radisys. All other trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220309005157/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SMBC and Toshiba Jointly Develop New Equity Indices Using Advanced Quantum-Driven Technologies28.5.2026 03:00:00 CEST | Press release
Sumitomo Mitsui Banking Corporation (“SMBC”) and Toshiba Corporation (“Toshiba”) today announced the joint development of the SMBC/TOSHIBA Quantum Driven Diversified Japan Equity Index and the SMBC/TOSHIBA Quantum Driven Diversified U.S. Equity Index, new equity indices realized with advanced quantum-driven technologies. Collectively, the indices are referred to as “SMBC/TOSHIBA Quantum Diversified” (the “Indices”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519448161/en/ Toshiba’s Simulated Bifurcation Machine 1. Background and Objectives Equity investment is central to asset management, but it also carries the ever-present risk of abrupt and substantial market fluctuations driven by geopolitical developments, changes in economic policy, and other external factors. In uncertain markets, investors are constantly seeking innovations in risk diversification that can protect their assets from unexpected market shocks. SM
BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 202627.5.2026 23:00:00 CEST | Press release
TEVIMBRA plus ZIIHERA and chemotherapy demonstrated statistically significant overall survival benefit with an unprecedented seven-month improvement in first-line HER2+ GEAOral presentation at ASCO highlights benefit regardless of PD-L1 status, including in PD-L1 <1% BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from HERIZON-GEA-01 were published in The New England Journal of Medicine and will be presented in an oral presentation (Rapid Oral Abstract: 4010) at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2026, in Chicago.The HERIZON-GEA-01 clinical trial evaluated ZIIHERA® (zanidatamab) plus chemotherapy, with and without TEVIMBRA® (tislelizumab), compared with the control arm of trastuzumab plus chemotherapy as first-line treatment for advanced/metastatic HER2+ gastroesophageal adenocarcinoma (GEA). Dr. Sun Young Rha, Professor of Medical Oncology at the Yonsei Cancer Center, Yonsei Univ
Stallergenes Greer Foundation Celebrates Excellence in Allergy Innovation With 2025 Awards27.5.2026 17:22:00 CEST | Press release
The Stallergenes Greer Foundation, dedicated to advancing allergy research, fostering innovation and addressing environmental factors which impact allergies, is delighted to announce the recipients of the 2025 edition of its prestigious Science Awards for Allergy. Building on the success of the previous edition, this year’s awards recognise outstanding contributions to allergy research and patient engagement and allocate a total of €100,000 to support these initiatives. Four researchers have been selected by the Board as award recipients, each receiving €25,000 across two categories: Innovation In Treatment Awards Assoc. Professor Alexander Eggel, PhD, Department for Biomedical Research, University of Bern, and Department of Rheumatology and Immunology, University Hospital Bern, Switzerland, recognised for his research: “Improving diagnostic and therapeutic options for allergic patients”; Dr Janice A. Layhadi, PhD, Research Associate, National Heart and Lung Institute, Imperial College
Capchase Secures $200M+, as Demand for Vendor Financing in Enterprise Tech Deals Accelerates27.5.2026 16:00:00 CEST | Press release
As buyers face tighter budgets, Capchase helps technology companies close more deals faster with AI-enabled instant financing Capchase, the leading vendor financing platform for enterprise tech, today announced $200M+ in incremental funding to scale its embedded financing infrastructure globally and deploy more AI-enabled features. The funding, a mix of debt warehouse facilities and equity backed by institutional investors, reflects market validation that vendor financing has become essential infrastructure for enterprise technology companies to sell hardware and software products. As global B2B buyers face tighter budgets and greater scrutiny over large, up-front purchases, financing demand is growing. The Market Shift: Financing as a Growth Lever for B2B Tech Companies The $1.3 trillion vendor financing market has been traditionally dominated by banks and other lenders that utilize multi-thread email chains to manual doc review for underwriting. Capchase replaces those bottlenecks wi
ClickHouse Tops $250M ARR and 4,000 Customers, Launches Claude-Powered Agents at Open House 202627.5.2026 15:00:00 CEST | Press release
Annual run-rate revenue more than tripled year-over-year; new CostBench benchmark shows ClickHouse Cloud at 23x better cost-performance than the nearest cloud data warehouse ClickHouse today opened Open House 2026, its second annual user conference, with a set of announcements that mark one of the company's most active quarters since founding. ClickHouse’s serverless cloud offering has crossed over $250 million in annual run-rate revenue — more than triple a year ago — and added more than 1,000 net new customers since January, bringing its total to 4,000. To meet the demands of AI-era workloads, the company also launched ClickHouse Agents, a fully managed agentic analytics service powered by Anthropic's Claude; published CostBench, an open benchmark comparing the major cloud data warehouses on cost-performance; and introduced House Mates, its first formal partner program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260527
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom